首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1481761

全球 HER2 抗體市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global HER2 Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年05月01日 | 出版商:

Value Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2032 年，全球 HER2 抗體市場需求將從 2023 年的 100.2 億美元達到近 170.7 億美元的市場規模，2024-2032 年研究期間複合年成長率為 6.1%。

HER2 抗體構成了一種用於治療 HER2 陽性乳癌的標靶治療形式，HER2 陽性乳癌是一種乳癌亞型，其特徵是人類表皮生長因子受體 2 (HER2) 蛋白過度表現。這些抗體與癌細胞上的 HER2 受體結合，阻斷其訊號傳導路徑並抑制細胞生長和增殖。透過專門針對 HER2 陽性癌細胞，這些抗體有助於選擇性殺死癌細胞，同時不傷害正常細胞，從而最大限度地減少副作用。 HER2 抗體療法通常與化療或其他標靶療法合併使用，以改善 HER2 陽性乳癌患者的治療結果和存活率。

市場動態

HER2 陽性乳癌（一種以 HER2 蛋白過度表現為特徵的乳癌亞型）的盛行率不斷上升，正在推動對 HER2 抗體等標靶治療的需求。 HER2 陽性乳癌在全球乳癌病例中佔很大比例，因此需要開發有效的治療方案來改善患者的預後。此外，分子診斷和生物標記測試的進步使醫療保健提供者能夠檢測出可能受益於 HER2 標靶治療的患者，進一步推動市場成長。此外，引入具有改進的功效、安全性和耐受性的新型 HER2 抗體可以擴大 HER2 陽性乳癌患者的治療選擇，從而推動市場成長。

此外，製藥公司、研究機構和醫療機構之間的合作推動了 HER2 抗體開發的創新，從而發現了新的治療標靶和聯合療法。此外，支持使用 HER2 抗體治療乳癌的監管批准和報銷政策正在推動市場擴張和可及性。然而，標靶治療和替代治療方案的進步可能會挑戰未來幾年的市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球 HER2 抗體市場的各個細分市場進行了包容性評估。 HER2 抗體產業的成長和趨勢為本研究提供了整體方法。

市場區隔

HER2 抗體市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按治療藥物

曲妥珠單抗
拉帕替尼
阿多曲妥珠單抗 Emtansine
帕妥珠單抗
依維莫司

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲 HER2 抗體市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。 HER2抗體市場的主要參與者包括諾華公司、輝瑞、F. Hoffmann-La Roche Ltd.、Abnova Corporation、InvivoGen、Celltrion Inc.、Biocon、Novus Biologicals。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 7 章：HER2 抗體公司的競爭格局

HER2抗體市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 8 章：公司簡介

頂級公司市佔率分析
市場集中度
Novartis AG

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd.

公司簡介
公司收入
產品
最近的發展

Abnova Corporation

公司簡介
公司收入
產品
最近的發展

InvivoGen

公司簡介
公司收入
產品
最近的發展

Celltrion Inc.

公司簡介
公司收入
產品
最近的發展

Biocon

公司簡介
公司收入
產品
最近的發展

Novus Biologicals

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114433

The global demand for HER2 Antibodies Market is presumed to reach the market size of nearly USD 17.07 Billion by 2032 from USD 10.02 Billion in 2023 with a CAGR of 6.1% under the study period 2024-2032.

HER2 antibodies constitute a form of targeted therapy employed in treating HER2-positive breast cancer, a breast cancer subtype characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. These antibodies bind to the HER2 receptors on cancer cells, blocking their signaling pathways and inhibiting cell growth and proliferation. By targeting HER2-positive cancer cells specifically, these antibodies help to selectively kill cancer cells while sparing normal cells, minimizing side effects. HER2 antibody therapies are often used in combination with chemotherapy or other targeted therapies to improve treatment outcomes & survival rates among patients with HER2-positive breast cancer.

MARKET DYNAMICS

The increasing prevalence of HER2-positive breast cancer, a subtype of breast cancer featured by overexpression of the HER2 protein, is driving demand for targeted therapies such as HER2 antibodies. HER2-positive breast cancer accounts for a significant proportion of breast cancer cases globally, necessitating the development of effective treatment options to improve patient outcomes. Additionally, advancements in molecular diagnostics and biomarker testing have enabled healthcare providers to detect patients likely to benefit from HER2-targeted therapies, further driving market growth. Moreover, introducing novel HER2 antibodies with improved efficacy, safety, and tolerability profiles expands treatment options for patients with HER2-positive breast cancer, driving market growth.

Furthermore, collaborations between pharmaceutical companies, research institutions, and healthcare organizations drive innovation in HER2 antibody development, resulting in the discovery of new therapeutic targets and combination therapies. Additionally, regulatory approvals and reimbursement policies supporting the use of HER2 antibodies in treating breast cancer are driving market expansion and accessibility. However, advancements in targeted therapies and alternative treatment options may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of HER2 Antibodies. The growth and trends of HER2 Antibodies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the HER2 Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Drugs

Trastuzumab
Lapatinib
Ado-trastuzumab Emtansine
Pertuzumab
Everolimus

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the HER2 Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the HER2 Antibodies market include Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Abnova Corporation, InvivoGen, Celltrion Inc., Biocon, Novus Biologicals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. HER2 ANTIBODIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Treatment Drugs
- 3.7.2 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL HER2 ANTIBODIES MARKET ANALYSIS BY TREATMENT DRUGS

5.1. Overview By Treatment Drugs
5.2. Historical and Forecast Data
5.3. Analysis By Treatment Drugs
5.4. Trastuzumab Historic and Forecast Sales By Regions
5.5. Lapatinib Historic and Forecast Sales By Regions
5.6. Ado-trastuzumab Emtansine Historic and Forecast Sales By Regions
5.7. Pertuzumab Historic and Forecast Sales By Regions
5.8. Everolimus Historic and Forecast Sales By Regions

6. GLOBAL HER2 ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

6.1. Regional Outlook
6.2. Introduction
6.3. North America Sales Analysis
- 6.3.1 Overview, Historic and Forecast Data Sales Analysis
- 6.3.2 North America By Segment Sales Analysis
- 6.3.3 North America By Country Sales Analysis
- 6.3.4 United States Sales Analysis
- 6.3.5 Canada Sales Analysis
- 6.3.6 Mexico Sales Analysis
6.4. Europe Sales Analysis
- 6.4.1 Overview, Historic and Forecast Data Sales Analysis
- 6.4.2 Europe By Segment Sales Analysis
- 6.4.3 Europe By Country Sales Analysis
- 6.4.4 United Kingdom Sales Analysis
- 6.4.5 France Sales Analysis
- 6.4.6 Germany Sales Analysis
- 6.4.7 Italy Sales Analysis
- 6.4.8 Russia Sales Analysis
- 6.4.9 Rest Of Europe Sales Analysis
6.5. Asia Pacific Sales Analysis
- 6.5.1 Overview, Historic and Forecast Data Sales Analysis
- 6.5.2 Asia Pacific By Segment Sales Analysis
- 6.5.3 Asia Pacific By Country Sales Analysis
- 6.5.4 China Sales Analysis
- 6.5.5 India Sales Analysis
- 6.5.6 Japan Sales Analysis
- 6.5.7 South Korea Sales Analysis
- 6.5.8 Australia Sales Analysis
- 6.5.9 South East Asia Sales Analysis
- 6.5.10 Rest Of Asia Pacific Sales Analysis
6.6. Latin America Sales Analysis
- 6.6.1 Overview, Historic and Forecast Data Sales Analysis
- 6.6.2 Latin America By Segment Sales Analysis
- 6.6.3 Latin America By Country Sales Analysis
- 6.6.4 Brazil Sales Analysis
- 6.6.5 Argentina Sales Analysis
- 6.6.6 Peru Sales Analysis
- 6.6.7 Chile Sales Analysis
- 6.6.8 Rest of Latin America Sales Analysis
6.7. Middle East & Africa Sales Analysis
- 6.7.1 Overview, Historic and Forecast Data Sales Analysis
- 6.7.2 Middle East & Africa By Segment Sales Analysis
- 6.7.3 Middle East & Africa By Country Sales Analysis
- 6.7.4 Saudi Arabia Sales Analysis
- 6.7.5 UAE Sales Analysis
- 6.7.6 Israel Sales Analysis
- 6.7.7 South Africa Sales Analysis
- 6.7.8 Rest Of Middle East And Africa Sales Analysis

7. COMPETITIVE LANDSCAPE OF THE HER2 ANTIBODIES COMPANIES

7.1. HER2 Antibodies Market Competition
7.2. Partnership/Collaboration/Agreement
7.3. Merger And Acquisitions
7.4. New Product Launch
7.5. Other Developments

8. COMPANY PROFILES OF HER2 ANTIBODIES INDUSTRY

8.1. Top Companies Market Share Analysis
8.2. Market Concentration Rate
8.3. Novartis AG
- 8.3.1 Company Overview
- 8.3.2 Company Revenue
- 8.3.3 Products
- 8.3.4 Recent Developments
8.4. Pfizer Inc.
- 8.4.1 Company Overview
- 8.4.2 Company Revenue
- 8.4.3 Products
- 8.4.4 Recent Developments
8.5. F. Hoffmann-La Roche Ltd.
- 8.5.1 Company Overview
- 8.5.2 Company Revenue
- 8.5.3 Products
- 8.5.4 Recent Developments
8.6. Abnova Corporation
- 8.6.1 Company Overview
- 8.6.2 Company Revenue
- 8.6.3 Products
- 8.6.4 Recent Developments
8.7. InvivoGen
- 8.7.1 Company Overview
- 8.7.2 Company Revenue
- 8.7.3 Products
- 8.7.4 Recent Developments
8.8. Celltrion Inc.
- 8.8.1 Company Overview
- 8.8.2 Company Revenue
- 8.8.3 Products
- 8.8.4 Recent Developments
8.9. Biocon
- 8.9.1 Company Overview
- 8.9.2 Company Revenue
- 8.9.3 Products
- 8.9.4 Recent Developments
8.10. Novus Biologicals
- 8.10.1 Company Overview
- 8.10.2 Company Revenue
- 8.10.3 Products
- 8.10.4 Recent Developments